company background image
VLA logo

Valneva ENXTPA:VLA Stock Report

Last Price

€2.40

Market Cap

€389.0m

7D

-7.3%

1Y

-58.6%

Updated

13 Nov, 2024

Data

Company Financials +

Valneva SE Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Valneva
Historical stock prices
Current Share Price€2.40
52 Week High€6.05
52 Week Low€2.23
Beta1.02
11 Month Change-5.00%
3 Month Change-31.97%
1 Year Change-58.60%
33 Year Change-88.58%
5 Year Change-3.97%
Change since IPO-78.14%

Recent News & Updates

€6.97: That's What Analysts Think Valneva SE (EPA:VLA) Is Worth After Its Latest Results

Nov 10
€6.97: That's What Analysts Think Valneva SE (EPA:VLA) Is Worth After Its Latest Results

Recent updates

€6.97: That's What Analysts Think Valneva SE (EPA:VLA) Is Worth After Its Latest Results

Nov 10
€6.97: That's What Analysts Think Valneva SE (EPA:VLA) Is Worth After Its Latest Results

Revenues Working Against Valneva SE's (EPA:VLA) Share Price Following 29% Dive

Sep 19
Revenues Working Against Valneva SE's (EPA:VLA) Share Price Following 29% Dive

Valneva SE (EPA:VLA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 17
Valneva SE (EPA:VLA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Valneva SE (EPA:VLA) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 10
Valneva SE (EPA:VLA) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Valneva SE's (EPA:VLA) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Apr 05
Valneva SE's (EPA:VLA) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Analyst Forecasts Just Became More Bearish On Valneva SE (EPA:VLA)

Mar 27
Analyst Forecasts Just Became More Bearish On Valneva SE (EPA:VLA)

Is Valneva (EPA:VLA) Weighed On By Its Debt Load?

Mar 15
Is Valneva (EPA:VLA) Weighed On By Its Debt Load?

News Flash: Analysts Just Made A Captivating Upgrade To Their Valneva SE (EPA:VLA) Forecasts

Jan 06
News Flash: Analysts Just Made A Captivating Upgrade To Their Valneva SE (EPA:VLA) Forecasts

Valneva (EPA:VLA) Has Debt But No Earnings; Should You Worry?

Dec 13
Valneva (EPA:VLA) Has Debt But No Earnings; Should You Worry?

Does Valneva (EPA:VLA) Have A Healthy Balance Sheet?

Aug 10
Does Valneva (EPA:VLA) Have A Healthy Balance Sheet?

Valneva SE's (EPA:VLA) Business And Shares Still Trailing The Industry

May 12
Valneva SE's (EPA:VLA) Business And Shares Still Trailing The Industry

Valneva (EPA:VLA) Takes On Some Risk With Its Use Of Debt

Jan 30
Valneva (EPA:VLA) Takes On Some Risk With Its Use Of Debt

Shareholder Returns

VLAFR BiotechsFR Market
7D-7.3%-4.0%-2.6%
1Y-58.6%-23.8%-3.4%

Return vs Industry: VLA underperformed the French Biotechs industry which returned -23.8% over the past year.

Return vs Market: VLA underperformed the French Market which returned -3.4% over the past year.

Price Volatility

Is VLA's price volatile compared to industry and market?
VLA volatility
VLA Average Weekly Movement7.3%
Biotechs Industry Average Movement6.9%
Market Average Movement4.4%
10% most volatile stocks in FR Market9.5%
10% least volatile stocks in FR Market2.3%

Stable Share Price: VLA's share price has been volatile over the past 3 months compared to the French market.

Volatility Over Time: VLA's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

FoundedEmployeesCEOWebsite
1998700Thomas Lingelbachvalneva.com

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus.

Valneva SE Fundamentals Summary

How do Valneva's earnings and revenue compare to its market cap?
VLA fundamental statistics
Market cap€389.04m
Earnings (TTM)-€7.42m
Revenue (TTM)€158.54m

2.5x

P/S Ratio

-52.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VLA income statement (TTM)
Revenue€158.54m
Cost of Revenue€163.61m
Gross Profit-€5.08m
Other Expenses€2.34m
Earnings-€7.42m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Mar 20, 2025

Earnings per share (EPS)-0.046
Gross Margin-3.20%
Net Profit Margin-4.68%
Debt/Equity Ratio79.4%

How did VLA perform over the long term?

See historical performance and comparison